Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. 1995

A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
Universität Lübeck, Abteilung Klinische Rheumatologie, Germany.

OBJECTIVE To examine the prevalence, subspecificities, and clinical associations of antineutrophil cytoplasmic antibodies (ANCA) in patients with systemic lupus erythematosus (SLE). METHODS One hundred fifty-seven sera from 120 patients with SLE were examined for classic (c) and perinuclear (p) pattern ANCA by indirect immunofluorescence. Antibody subspecificities were determined by enzyme-linked immunosorbent assay (ELISA). Serologic results were correlated with clinical manifestations as categorized by the BILAG (British Isles Lupus Assessment Group) index. RESULTS ANCA were found in 40 of the 157 sera (25%). Only a pANCA, not a cANCA, pattern of fluorescence was seen. By ELISA testing, 16 sera reacted to lactoferrin, 8 to elastase, and 4 to lysozyme. There was no reactivity to proteinase 3 (PR3) or myeloperoxidase (MPO). No correlation of pANCA, or any of the ANCA subspecificities, with organ system involvement, as categorized by the BILAG index, was found. Notably, there was no correlation of ANCA results with lupus vasculitis. CONCLUSIONS The absence of cANCA, anti-PR3, and anti-MPO shows that with appropriate assay conditions, ANCA testing assists in the differentiation between SLE and the ANCA-associated vasculitides. The lack of a correlation between pANCA or any ANCA subspecificity and clinical manifestations suggests that ANCA do not identify particular clinical subsets among SLE patients, including those with lupus vasculitis.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences

Related Publications

A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
September 1994, The Journal of rheumatology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
January 1992, Contributions to nephrology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
July 1996, British journal of rheumatology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
January 1998, Clinical rheumatology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
July 2001, Rheumatology international,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
November 1999, The Journal of rheumatology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
January 2002, Clinical and experimental dermatology,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
August 2004, The Medical journal of Malaysia,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
January 2003, Lupus,
A Schnabel, and E Csernok, and D A Isenberg, and C Mrowka, and W L Gross
December 1976, Zhonghua Minguo wei sheng wu xue za zhi = Chinese journal of microbiology,
Copied contents to your clipboard!